BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 33591888)

  • 21. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.
    Chen JH; Bahri S; Mehta RS; Kuzucan A; Yu HJ; Carpenter PM; Feig SA; Lin M; Hsiang DJ; Lane KT; Butler JA; Nalcioglu O; Su MY
    Radiology; 2011 Dec; 261(3):735-43. PubMed ID: 21878615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.
    Minarikova L; Bogner W; Pinker K; Valkovič L; Zaric O; Bago-Horvath Z; Bartsch R; Helbich TH; Trattnig S; Gruber S
    Eur Radiol; 2017 May; 27(5):1901-1911. PubMed ID: 27651141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
    Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
    Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors Affecting Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: Development and Validation of a Predictive Nomogram.
    Kim SY; Cho N; Choi Y; Lee SH; Ha SM; Kim ES; Chang JM; Moon WK
    Radiology; 2021 May; 299(2):290-300. PubMed ID: 33754824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
    J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Total choline quantification measured by 1H MR spectroscopy as early predictor of response after neoadjuvant treatment for locally advanced breast cancer: The impact of immunohistochemical status.
    Drisis S; Flamen P; Ignatiadis M; Metens T; Chao SL; Chintinne M; Lemort M
    J Magn Reson Imaging; 2018 Oct; 48(4):982-993. PubMed ID: 29659077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applying a new quantitative global breast MRI feature analysis scheme to assess tumor response to chemotherapy.
    Aghaei F; Tan M; Hollingsworth AB; Zheng B
    J Magn Reson Imaging; 2016 Nov; 44(5):1099-1106. PubMed ID: 27080203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
    Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
    Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Prediction of Breast Cancer Therapy Response using Multiresolution Fractal Analysis of DCE-MRI Parametric Maps.
    Machireddy A; Thibault G; Tudorica A; Afzal A; Mishal M; Kemmer K; Naik A; Troxell M; Goranson E; Oh K; Roy N; Jafarian N; Holtorf M; Huang W; Song X
    Tomography; 2019 Mar; 5(1):90-98. PubMed ID: 30854446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging.
    Martincich L; Montemurro F; De Rosa G; Marra V; Ponzone R; Cirillo S; Gatti M; Biglia N; Sarotto I; Sismondi P; Regge D; Aglietta M
    Breast Cancer Res Treat; 2004 Jan; 83(1):67-76. PubMed ID: 14997056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
    Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
    Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic Contrast-enhanced Breast MRI for Evaluating Residual Tumor Size after Neoadjuvant Chemotherapy.
    Kim SY; Cho N; Park IA; Kwon BR; Shin SU; Kim SY; Lee SH; Chang JM; Moon WK
    Radiology; 2018 Nov; 289(2):327-334. PubMed ID: 30152744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy.
    Martincich L; Montemurro F; Cirillo S; Marra V; De Rosa G; Ponzone R; Aglietta M; Regge D
    Radiol Med; 2003; 106(1-2):51-8. PubMed ID: 12951551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge.
    Li W; Partridge SC; Newitt DC; Steingrimsson J; Marques HS; Bolan PJ; Hirano M; Bearce BA; Kalpathy-Cramer J; Boss MA; Teng X; Zhang J; Cai J; Kontos D; Cohen EA; Mankowski WC; Liu M; Ha R; Pellicer-Valero OJ; Maier-Hein K; Rabinovici-Cohen S; Tlusty T; Ozery-Flato M; Parekh VS; Jacobs MA; Yan R; Sung K; Kazerouni AS; DiCarlo JC; Yankeelov TE; Chenevert TL; Hylton NM
    Radiol Imaging Cancer; 2024 Jan; 6(1):e230033. PubMed ID: 38180338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic Performance of MRI, Molecular Breast Imaging, and Contrast-enhanced Mammography in Women with Newly Diagnosed Breast Cancer.
    Sumkin JH; Berg WA; Carter GJ; Bandos AI; Chough DM; Ganott MA; Hakim CM; Kelly AE; Zuley ML; Houshmand G; Anello MI; Gur D
    Radiology; 2019 Dec; 293(3):531-540. PubMed ID: 31660801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.
    Baek HM; Chen JH; Nie K; Yu HJ; Bahri S; Mehta RS; Nalcioglu O; Su MY
    Radiology; 2009 Jun; 251(3):653-62. PubMed ID: 19276320
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor angiogenesis change estimated by using diffuse optical spectroscopic tomography: demonstrated correlation in women undergoing neoadjuvant chemotherapy for invasive breast cancer?
    Pakalniskis MG; Wells WA; Schwab MC; Froehlich HM; Jiang S; Li Z; Tosteson TD; Poplack SP; Kaufman PA; Pogue BW; Paulsen KD
    Radiology; 2011 May; 259(2):365-74. PubMed ID: 21406632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.